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Resumo 
 
Os gliomas são os tumores primários mais frequentes do Sistema Nervoso Central, 
representando 50% de todos os casos de tumores cerebrais. Incluem, entre outros, os 
astrocitomas (AT) e os oligodendrogliomas (OLG).  
Uma designação comum para estes tumores, quando se localizam num ou mais lobos cerebrais, 
na região supratentorial é a de gliomas difusos e atingem, caracteristicamente, jovens adultos.  
Esses dois tipos de gliomas são considerados de baixo grau e são infiltrativos, de crescimento 
lento. Os gliomas de baixo grau – grau II, pela Organização Mundial de Saúde – tem uma forte 
tendência para a progressão maligna, para gliomas anaplásicos (grau III, pela OMS) e até 
glioblastomas secundários (grau IV, pela OMS), o que, muitas vezes, ocorre após alguns anos, 
geralmente, entre cerca de 4 a 5.  
Muitas vezes, após uma resseção cirúrgica de gliomas de baixo grau, as células neoplásicas 
deixadas no cérebro podem originar um tumor recidivante, que muitas vezes se transforma em 
glioma de alto grau, com prognóstico variável a longo prazo e uma taxa de sobrevida de entre 5 
a 8 anos. 
A nova classificação da OMS, no que diz respeito a Tumores do Sistema Nervoso Central, 
revista em 2016, introduziu parâmetros moleculares como mutações IDH, co-deleções de 
1p/19q e perdas de ATRX, agrupando os tumores em categorias de acordo com seus perfis 
genéticos, além dos padrões histológicos usados até então. 
Sendo assim, é possível classificar os gliomas difusos em astrocitomas, IDH mutantes; 
oligodendrogliomas, IDH mutantes e 1p/19q co-deletados; astrocitomas IDH wild-type; 
glioblastomas IDH mutantes; glioblastomas IDH wild-type; oligodendrogliomas sem outras 
especificações; astrocitomas sem outras especificações; oligoastrocitomas sem outras 
especificações e glioblastomas sem outras especificações. 
Os critérios usados para definir o grau de anaplasia dos gliomas, definidos pela OMS, são 
polimorfismo nuclear e hipercromasia, índice mitótico, proliferação endotelial da 
microvascularização tumoral e necrose do parênquima tumoral. Estes critérios permitem aos 
patologistas classificar os gliomas difusos em diferentes graus de malignidade, desde grau II, o 
menos maligno, até aos graus III e IV, os mais malignos, dos quais o glioblastoma é o mais 
comum. 
As alterações moleculares no processo de tumorigénese levam à ativação de oncogenes ou à 
inativação de genes supressores de tumor. 
Alguns dos marcadores genéticos de grande relevância no processo de tumorigénese e na 
determinação do tipo e grau de anaplasia dos gliomas difusos são o 1p/19q (co-deleção), o 
EGFR, o PTEN e o CDKN2A. 
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A presença de mutação do ATRX ajuda ao diagnóstico dos AT com IDH mutante, distinguindo-
os dos OLG. Os AT anaplásicos com mutações combinadas no ATRX e no IDH têm melhor 
prognóstico do que os que só têm a mutação do IDH. 
As mutações no codão 132 do gene IDH ocorrem cedo e a uma frequência elevada em AT, OLG 
de graus II e III, e em glioblastomas secundários desenvolvidos a partir de AT. 
Os objetivos deste estudo são comparar o perfil imunohistoquímico e as alterações citogenéticas 
encontradas em 16 casos de doentes com cirurgia a gliomas primários de baixo grau, e a 
recidiva de grau mais elevado, resultando num total de 32 amostras – 18 oligodendrogliomas, 
10 astrocitomas, 3 oligoastrocitomas e 1 gliossarcoma; avaliar e quantificar as alterações e 
identificar subpopulações baseadas em marcadores, nas amostras de tumores de ambas as 
cirurgias.  
Para isso, obtiveram-se lâminas de imunohistoquímica e fizeram-se blocos de Tissue Micro 
Arrays, dos quais se obtiveram lâminas para Hibridação In Situ por Fluorescência. 
As proteínas estudadas foram GFAP, IDH1, KI-67, ATRX e Olig-2, e os genes foram CDKN2A, 
p53, EGFR, PTEN, 1p e 19q. 
Realizou-se a técnica de imunohistoquímica para os marcadores IDH, ATRX e GFAP, 
posteriormente fotografados no microscópio ótico, e analisados com programa Image-J (plugin 
Colour Deconvolution). Às áreas de interesse foram-lhes atribuídas cores secundárias (cada uma 
associada a um marcador) e as imagens resultantes foram sobrepostas originando áreas de cores 
primárias. Foi calculado o rácio de pixéis de cada cor de interesse. Realizou-se igualmente a 
técnica de imunohistoquímica para os marcadores Olig-2 e KI-67, também fotografados no 
microscópio ótico e analisados no programa Image-J (plugin ImmunoRatio). 
Realizou-se ainda Hibridação in situ de fluorescência, para analisar os genes CDKN2A, p53, 
EGFR, PTEN, 1p e 19q, em lâminas de Tissue Micro Array, que foram fotografadas no 
microscópio de fluorescência e analisadas no programa Image-J (plugin Cell Counter para 
contagem dos núcleos). 
Este estudo incluiu 18 oligodendrogliomas, 10 astrocitomas, 3 oligoastrocitomas e 1 
gliossarcoma. 
A análise foi feita inicialmente para os marcadores individuais e, em seguida, para as 
subpopulações definidas, baseadas na classificação actual de gliomas difusos. 
Nenhuma das amostras estudadas apresentou deleção do gene supressor tumoral PTEN.  
O estudo de EGFR mostrou amplificação em apenas 6 das 32 amostras, sendo 4 exclusivamente 
nas recidivas e 1 exclusivamente num tumor primário de baixo grau.  
O p53 estava mutado em 6 das 32 amostras estudadas, sendo que 4 desses 6 tumores com 
mutação eram recidivas. Analisando as alterações de primários para recidivas, encontraram-se 4 
casos com p53 wild-type no primário e mutação nas recidivas e 1 caso que manteve a mutação 
em ambos os grupos.  
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O CDKN2A estava deletado no primário e na recidiva em simultâneo, em apenas 1 caso. 6 casos 
tinham deleções nos primários e apenas 3 tinham deleções nas recidivas.  
A expressão de KI-67 apresentou valores mais elevados nas recidivas do que nos primários. 
Relativamente à expressão de Olig-2, observou-se o contrário, sendo os valores mais elevados 
nos primários do que nas recidivas.  
Não se encontraram diferenças major nas três subpopulações estudadas (IDH1mut/ATRXloss, 
IDH1mut/ATRX/1p/19q co-deletadas e IDH1wt) entre as amostras de tumores primários e as 
suas respectivas recidivas.  
Descobriram-se mais células tumorais IDH1mut/ATRXloss em recidivas (9799±24384) do que 
em primários (5053±10116), e mais células tumorais IDH1- em primários (671939±180448) do 
que nas recidivas (609653±284091). Contudo, estas diferenças não foram muito evidentes.  
Células IDH1mut/ATRX/1p/19q co-deletadas foram encontradas em apenas um dos dezasseis 
casos estudados.  
As proteínas e genes estudados cobrem a maioria das principais vias de sinalização molecular 
que levam ao desenvolvimento de carcinomas. Contudo, a ausência de variações muito 
evidentes entre os dois grupos comparados (primário e respetiva recidiva) indica que poder-se-á 
não estar a estudar os marcadores mais relevantes para esta evolução. 
Outros marcadores que poderão ser relevantes são o PDGF e o Ras. 
O PDGF é um agente mitogénico de células mesenquimais, incluindo células gliais e já foi 
associado a glioblastomas (vias PI3k/AKT e Ras-Raf-Mek-Erk). O gene Ras foi o primeiro 
oncogene humano a ser identificado e sabe-se que está mutado em cerca de um terço dos 
carcinomas. Estes são apenas dois exemplos de outras moléculas que podem ser estudadas nos 
gliomas. 
Este estudo é um passo noutra direcção, no que diz respeito aos marcadores biológicos em 
gliomas. Os resultados obtidos levantam variadas questões face aos marcadores estudados e 
oferecem uma série de sugestões de outros a considerar; e, uma vez que não há bibliografia de 
suporte, seria interessante continuar a estudar esta linha de progressão tumoral do primário para 
a recidiva. O objetivo não seria apenas caracterizar subgrupos histológicos de gliomas do ponto 
de vista genético e molecular mas também, e acima de tudo, tentar compreender a evolução do 
tumor primário e os mecanismos e ferramentas biológicas presentes no próprio, que lhe permite 
recidivar com um nível de malignidade superior. Se se conseguir prever estas transformações no 
tempo, poder-se-á tentar controlar a progressão da doença logo desde o momento do 
diagnóstico. 
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Abstract 
 
The most frequent primary tumors of the Central Nervous System are gliomas, representing 
50% of all brain tumor cases, which include, among others, astrocytomas and 
oligodendrogliomas.  
Those two types of gliomas, considered low-grade gliomas, are infiltrative and slow-growing. 
Low-grade gliomas (World Health Organization grade II) have a strong tendency for malignant 
progression to anaplastic gliomas (World Health Organization grade III) and even secondary 
glioblastomas (World Health Organization grade IV), which often takes place after a few years, 
usually about 4 to 5.  
Indeed, after a surgical resection of LGG, cancerous cells left in the brain can give rise to a 
recurrent tumor, often transformed in a high-grade glioma, with variable long-term prognoses 
and a survival rate between 5 to 8 years. 
The new World Health Organization Classification of Tumors of the Central Nervous System, 
revised in 2016, introduced molecular parameters, such as IDH mutations, 1p/19q co-deletions 
and ATRX losses, for grouping tumors into categories according to their genetic profiles besides 
the histologic patterns used until then.  
The aim of this study is to compare immunohistochemical profile and cytogenetic changes in 16 
cases with two different surgeries from the same patient, treated for recurrences, evaluate and 
quantify those changes and identify marker based subpopulations in tumour samples from both 
surgeries. The proteins studied were GFAP, IDH1, KI-67, ATRX and Olig-2, and the genes were 
CDKN2A, p53, EGFR, PTEN, 1p and 19q. 
We did not found major differences in the populations we studied (IDH1mut/ATRXloss, 
IDH1mut/ATRX/1p/19q co-del and IDH1wt) between primaries and their relapses. 
However, differences were found in Ki-67, Olig-2, EGFR and CDKN2A between the two 
groups studied (primary tumors and relapses). 
All proteins and genes studied cover most of the main pathways that lead to cancer 
development, which may lead us to think that we are looking at the wrong set of markers.  
We found some results that suggest it should be interesting to continue this type of research of 
comparing primary tumors with their own relapses, and try to understand what makes tumors 
relapse in a much more aggressive form, in order to control the progression of the disease right 
in the moment of the diagnosis. 
 
Keywords: low-grade gliomas; subpopulations; primary tumors, relapse tumors, FISH, IHQ  
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1. Introduction 
1.1 Diffuse Gliomas 
Central Nervous System (CNS) primary tumors account for 2% of all tumors and are 
associated with high mortality rates, being one of the most devastating cancers. These 
tumors often show locally aggressive behaviour and cannot be cured by recurrent 
therapies.[1,2] The most frequent are gliomas, representing 50% of all brain tumor 
cases, which include, among others, astrocytomas (AT) and oligodendrogliomas 
(OLG).[1,2]  
A common designation for these tumors when located on one or more cerebral lobes, on 
the supratentorial floor, is diffuse gliomas (DG), characteristically affecting younger 
adults.   
Until the last revision of the World Health Organization (WHO), their pathological 
classification was centred on the histomorphological characteristics, based on the 
resemblance of their cells with normal glial cells tissue of origin, complemented by 
immunohistochemistry techniques (IHC).[1,2]  
Those two types of gliomas considered low-grade gliomas (LGG) are infiltrative and 
slow-growing. LGG (WHO grade II) have a strong tendency for malignant progression 
to anaplastic gliomas (WHO grade III) and even secondary glioblastomas (WHO grade 
IV), which often takes place after a few years, usually about 4 to 5.[3] Indeed, after a 
first surgical resection of LGG, the cancerous cells left in the brain can give rise to a 
recurrent tumor, often transformed in high-grade glioma, with variable long-term 
prognoses and survival rates between 5 to 8 years.[4]   
The new WHO Classification of Tumors of the CNS, revised in 2016, introduced 
molecular parameters, such as IDH mutations, 1p/19q co-deletions and ATRX losses, 
grouping tumors into categories according to their genetic profile besides histologic 
patterns, as shown in Figure 1.[4] Therefore, we can classify DG into Diffuse AT, IDH 
mutant; OLG, IDH mutant and 1p/19q co-deleted; Diffuse AT IDH-1 wild-type; 
Glioblastoma (GB), IDH mutant; GB IDH wild-type; OLG, No other specification 
(NOS); AT, NOS; Oligoastrocytomas (OLGA), NOS and GB, NOS (Figure 1).[4] 
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Figure 1 - A simplified algorithm for classification of the diffuse gliomas, 2016 CNS WHO [4] 
 
Histological criteria used for grading DG anaplasia, as defined by WHO, are 
nuclear polymorphism and hyperchromasia, mitotic index, endothelial proliferation 
of tumor microvascularisation vessels and tumor parenchyma necrosis. These 
criteria allow pathologists to classify DG into different degrees of malignancy, from 
II, the most benign, to III and IV, the most malignant, of which GB is the most 
common.[2,3] 
Molecular criteria with prognostic value, in addition to histological ones, includes 
several markers [4] among which, ATRX and IDH (mutation r132) are two of the 
most used in neuropathological diagnosis.[5-7] 
1.2 Gene and Protein Expressions  
Molecular alterations occurring during tumorigenesis lead to oncogene activation or 
tumor suppressor gene inactivation. 
Some genetic markers with great relevance in tumorigenesis and in determining type 
and degree of DG anaplasia are 1p19q (co-deletion), EGFR, PTEN and CDKN2A.[8] 
Korshunov et al. have successfully used Fluorescent In Situ Hybridization (FISH) 
probes for these markers to obtain clinically useful information for 114 high-grade 
gliomas, morphologically ambiguous, composed of small cells.[9] Another study, 
performed to detect only PTEN and EGFR, including tissue samples confirmed by 
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biopsy of 63 cases of anaplastic astrocytoma (AAT) and 111 cases of glioblastoma 
multiform, demonstrated clinical significance of these markers.[10] 
The presence of mutated ATRX helps the diagnosis of AT with an IDH mutation, 
distinguishing them from OLG. Anaplastic AT with combined ATRX and IDH 
mutations has better prognosis than those with only IDH mutation.[5] Mutations at 
codon 132 of the IDH gene occur early and with a high frequency in AT and OLG 
grades II and III, and in secondary GB developed from AT.[5] 
 
1.2.1 IDH  
In 2008, a multi-group collaboration sequenced over 20,000 genes in 22 GB and 
identified a common point mutation in IDH1 in 12% of the analysed samples.[11]  
Further studies found that this mutation is present in 80% of grade II-III gliomas and 
secondary GB.[9-11] Mutations in IDH2 have also been identified in gliomas, although 
they are much less common and mutually exclusive with IDH1 mutations.[9, 12, 13] 
Also, IDH1 is detectable by IHC techniques, or gene sequencing, when negative or any 
other justified cases, which make this protein suitable for diagnosis routine. 
All mutations identified until now have a single amino-acid missense mutation in IDH1 
at arginine 132 (R132) or the analogous residue in IDH2 (R172). This residue is located 
at the enzyme active site and is critical for isocitrate binding.[17] Before these 
observations, mutation of IDH genes had never been linked to cancer.[15]  
Isocitrate dehydrogenase 1 (IDH1) catalyses the oxidative decarboxylation of isocitrate 
to 2-oxoglutarate (Figure 2). 
 
Figure 2- Neomorphic enzyme activity of mutant IDH enzymes. IDH1 and IDH2 catalyse the oxidative 
decarboxylation of isocitrate to generate αKG, using NADP+ as a cofactor and producing NADPH and CO2. 
Recurrent mutations in the active site of IDH1 and IDH2 confer a gain of function activity that catalyses the 
conversion of αKG into D2HG in a manner that consumes NADPH. [18] 
 
The mutation at R132 inactivates the protein’s ability to bind isocitrate and abolishes its 
normal catalytic activity. This result in reduced levels of α-KG and NADPH, important 
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cofactor necessary to maintain normal levels of reduced glutathione to combat reactive 
oxygen species.[15-16] Somatic mosaicism for IDH1 or IDH2 at R132 causes 
enchondromatosis syndromes, Ollier’s disease and Maffucci syndrome, which are 
characterized by haemangiomas and cartilaginous tumors, which carry an increased risk 
for gliomas.[21] Also, introducing of mutated IDH into normal cells causes increased 
proliferation, increased colony formation, and inability to differentiate.[22]  
 
1.2.2 ATRX  
ATRX gene was first discovered through a study of the X-linked mental retardation 
(MR) syndrome (ATRX syndrome) with patients presenting α-thalassemia, severe 
psychomotor impairments, urogenital abnormalities, and patterns of characteristic facial 
dimorphism.[23] 
ATRX protein exists in two isoforms (180 and 280 kDa) and is highly enriched at GC-
rich and repetitive sequences.[24,25] The C-terminus of ATRX protein harbors an 
helicase/ATPase domain, classifying ATRX as part of SNF2 (SWItch/Sucrose Non-
Fermentable 2) family of chromatin-remodelling proteins.[26] 
Further confirming the ATRX function as a regulator of chromatin remodelling and 
transcription is evidence of the formation of an ATP-dependent complex with 
transcription cofactor DAXX. In addition, ATRX also alters the DNase I digestion 
pattern and triple helix displacement activity.[27] 
ATRX has been found at pericentromeric heterochromatin, ribosomal DNA arrays on 
acrocentric chromosomes, telomeres and Pro Myelocytic Leukemia (PML) nuclear 
bodies within mouse and human cells.[27-29] Consequently, ATRX plays a key role in 
gene expression regulation and therefore in cancer (Figure 3).[28]  
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Figure 3 – ATRX from PML bodies and ribosomal DNA remodelling chromatin through the consumption of 
ATP. [30] 
ATRX inactivation within gliomas can be due to mutations, deletions, gene fusions or a 
mix of these causes.[31] Ikemura et al. have demonstrated viability of detecting ATRX 
protein expression using IHC and correlating these expression levels with mutation 
status, which simplifies the incorporation of ATRX analysis in clinical practice.[31] 
Nowadays, IHC analysis of ATRX is determinant in diagnosis and is currently a practice 
in most places, although genetic sequencing is also performed in some laboratories. 
Furthermore, ATRX mutations correlate with other prominent features, including 
Alternative Lengthening of Telomeres (ALT) phenotype, TP53 mutations, and occur 
most often in astrocytic tumors. Interestingly, Kannan et al. [32] reported that within 
their cohort, mutations related to ATRX cofactor DAXX were not found in LGGs and 
therefore in these tumors, interactions with histone is not as important perhaps. 
 
1.2.3 1p19q  
Specific gene mutations, loss of heterozygosity, deletions and/or amplifications of entire 
chromosomal regions were described in specific tumours including gliomas. Gliomas 
are characterized particularly by chromosomal deletions, inappropriately activated 
intracellular signalling pathways, and/or activity loss of tumour suppressor proteins.[35-
36] Co-deletion of chromosome 1p/19q is the main loss of heterozygosity studied in 
gliomas and is associated with a good prognosis and increased responsiveness to 
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chemotherapy. High incidence of 1p and 19q deletion is observed in OLG and OLGA 
[35] and 1p36-19q13 deletions are closely associated with typical OLG histology, a 
longer progression-free time and longer median survival time, thus representing an 
independent prognostic factor in Anaplastic OLG (AOLG) tumors (WHO grade 
III).[36-37]  
This genetic aberration was identified in 1994 and became the first biomarker in neuro-
oncology. [35]  
Boots-Sprenger, S. et al detected complete 1p/19q co-deletion in 34% of low-grade 
gliomas, 52% of anaplastic gliomas and 3% of glioblastomas, and confirmed again that 
patients with low-grade or anaplastic gliomas with complete 1p/19q co-deletion were 
associated to a significant survival benefit.[38] 
Wharton, et al. also detected 1p and 19q in most of the samples classified as OLG, 
either WHO grade II or III. [39] 
1.2.4 EGFR 
EGFR was the first discovered epidermal growth factor receptor, also known as ErbB-1. 
Many cancers have been associated with upregulation of EGFR and its overexpression 
has been identified in the majority of solid tumors, including gliomas.[40] While normal 
cells express 40,000 to 100,000 EGFR receptors, cancer cells may express up to 
2,000,000 receptors.[40] Stimulation of overexpressed EGFR receptors may contribute 
to cancer-cell proliferation while simultaneously blocking apoptosis, activating invasion 
and stimulating tumor-induced neovascularization. The degree of overexpression 
correlates with tumor progression, resistance to chemotherapy and poor prognosis.[40] 
EGFR gene amplification and overexpression are rare in low-grade gliomas but are very 
typical in GB, being its most common mutant named EGFRvIII.[43-44] EGFRvIII is 
unable to bind its ligand due to a deletion of 267 amino-acids from the receptor 
extracellular domain, making it signal constitutively. The wild-type (WT) receptor is 
usually co-expressed with the mutated form in GB [44-45] but there are a number of 
studies [46-47] demonstrating that the mutated form is more tumorigenic than its WT 
receptor, suggesting EGFRvIII signalling plays a key role in gliomagenesis. [41] This 
increased expression may influence multiple aspects of tumor biology, such as survival, 
cell proliferation, motility and invasiveness, and even resistance to treatments.[45-46]  
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1.2.5 PTEN 
PTEN was identified in 1997 as a tumor-suppressor gene, by Li et al.[47]  
The homologous phosphatase and tensin gene (PTEN) mutation in chromosome 10q23 
is detected in a wide variety of human cancers, with a frequency comparable to the one 
of p53 gene.[48] Both this proteins are tumor suppressors. PTEN encodes a lipid 
phosphatase pathway that negatively regulates phosphoinositol-3-kinase/Akt.[49] The 
loss of alleles in chromosome 10q is one of the most observed in gliomas.[50] 
A PTEN FISH study with 217 samples from astrocytoma with diffuse infiltration 
regions showed significant correlation with histological grade. Clinical results 
corroborated the usefulness of associating histological interpretation with molecular 
biology.[51] 
PTEN protein–protein interactions can also affect its tumour suppressor properties.[52] 
In last year’s paper, Benitez, J. et al reported a novel chromatin-associated function of 
PTEN tumour suppressor that represses oncogene expression and tumour growth in 
patient-derived glioma xenografts through DAXX-H3.3 association. They show that 
DAXX physically interacts with PTEN, and PTEN regulates H3.3 loading on chromatin 
by limiting DAXX interactions with this histone, and thereby controls expression of 
several tumour-promoting genes.[52] 
Also, Shen, W. et al demonstrated PTEN’s essential role in chromosomal stability 
maintenance, through physical interaction with centromeres and control of DNA, 
preventing double-strand breaks.[53]  
 
1.2.6 CDKN2A 
CDKN2A, also known as cyclin-dependent kinase Inhibitor 2A is a gene which in 
humans is located at chromosome 9, band p21.3 [57] and codes for two proteins 
including INK4 family member p16 (or p16INK4a) and p14arf.[58-59] Both regulate 
cell cycle, acting as tumor suppressors. p16 inhibits cyclin dependent kinases 4 and 6, 
activating the retinoblastoma family of proteins and blocking the progression from G1 
to S-phase.[58-59] 
CDKN2A somatic mutations are common in the majority of human cancers, with 
estimates that CDKN2A is the second most commonly inactivated gene in cancer after 
p53, including gliomas.[56,57] Studies have confirmed the relationship between 
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homozygous deletion of CDKN2A and malignant tumor progression, suggesting this 
marker relates with worst prognosis in anaplastic OLG.[38-58]  
In a study in 189 samples of patients under the age of 50, with confirmed glioblastoma, 
Korshunov et al. detected that chromosome 9p21 deletion is related to an unfavourable 
prognosis.[9]
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2. Objectives 
Considering that DG are histomorphologically very heterogeneous and harbour different 
variable prognosis, it is important to stratify patients for their risk level of recurrence. 
To achieve this goal, we hypothesize that histomorphological and molecular analysis 
could allow us to conclude relevant prognostic significance. The study aimed to:  
 Compare IHC profile and cytogenetic changes from two different surgeries from 
the same patient, treated for recurrences; 
 Identify marker based subpopulations in tumour sample from both surgeries. 
 
  
23 
 
3. Ethical Considerations 
The study is based on the analysis of human samples, from archives, using formalin 
fixed paraffin embedded samples, previously used to obtain a diagnosis. 
The patients’ confidentiality was maintained as samples were identified with letters (A 
to AF) and only the following variables were considered for the study: age, gender and 
location of the tumor. 
A digital log book was created, identifying only cases and variables and never the 
personal data of the patients. 
The project was presented for approval to the Ethics Committee of the Centro 
Académico de Medicina de Lisboa, and approved with the reference: 442/16. 
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4. Material and Methods 
4.1 Sampling Method  
Cases were selected from the Laboratory of Neuropathology (LN) database. Sampling 
was achieved using diagnosis as criteria for classification, preserving patients’ 
confidentiality and limiting the access to personal data. 
The study aimed to evaluate samples from patients with low grade anaplasia DG, who 
relapsed with a higher grade tumor. The selection was based on the following criteria 
(Figure 4): 
1. Diagnosis of diffuse glioma; 
2. Diffuse gliomas cases whose patients were submitted to two or more surgical 
ressections; 
3. Only samples with enough biological material to be used and still remain on 
archive for any eventual neuropathological techniques.  
  
 
 
 
 
 
 
 
 
 
 
 
 
Sixteen patients were selected, representing 32 paraffin blocks. From cases with more 
than one block, only one from each surgery was selected, based on major tumor 
representativity. 
From each block, 5 slides with 2μm sections were obtained using a Minot microtome 
(Leica RM2145), for IHC techniques, in the following order: GFAP, IDH1, KI-67, 
ATRX and Olig-2.   
 
 
Diffuse Gliomas 
2 or more surgical 
interventions 
Only 1 surgical 
intervention 
Excluded Not enough 
biological material in 
paraffin block 
Enough biological 
material in paraffin 
block 
Excluded Included 
Figure 4- Sampling criteria 
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Then, Tissue Micro Array (TMA) was performed with 30 of the 32 paraffin blocks, to 
obtain 2 new TMA blocks with samples from each case, for FISH technique. The 
punched areas were selected, based on the IHC analysis that revealed major tumor areas 
of interest. The remaining 2 blocks, that didn’t go through TMA, were analysed in their 
totality due to its limited amount of sample. Sections from these blocks (two TMA and 
two original) were obtained at 5μm, for the following probes: CDKN2A, EGFR, PTEN, 
p53, 1p and 19q. 
 
4.2 Immunohistochemistry 
Sections were dewaxed and rehydrated through decreasing alcohol concentrations to 
water. Endogenous peroxidase was blocked using a 3% hydrogen peroxide solution for 
ten minutes. Microwave antigen retrieval was performed for ten minutes at 600W 
followed by twenty minutes at 850W, using H3300 vector citrate buffer. Slides were 
rinsed in phosphate buffered saline (PBS) and incubated with the respective primary 
antibody, overnight (ON) at 4ºC. 
Sections were then rinsed twice in PBS and incubated with secondary antibody, Dako 
REAL™ Envision™ HRP Rabbit/Mouse, for 1 hour at room temperature (RT). Slides 
were rinsed in PBS, stained with 3,3’-diaminobenzidine (DAB) solution for five 
minutes and rinsed in tap water. Counterstain was provided by Harris Hematoxylin for 4 
minutes, and then slides were then differentiated, blued with 1% ammoniacal water, 
dehydrated, cleared and mounted with synthetic mounting media, Entellan® (Appendix 
1). 
4.3 Fluorescent In Situ Hybridization  
As in the previous procedure, slides with the sections were dewaxed and rehydrated 
through decreasing alcohol concentrations to water. Microwave antigen retrieval was 
performed for 10 minutes at 600W followed by 20 minutes at 850W, using in H3300 
vector citrate buffer. Slides were rinsed, following Vysis Paraffin Pretreatment IV & 
Post-Hybridization Wash Buffer Kit in a pre-hybridization solution of Sodium 
thiocyanate, pre-heated in the oven at 82ºC, for 10 minutes. After a quick rinse in 
ethanol, slides were incubated for 10 minutes in Pepsin solution (Vysis Protease IV), at 
37ºC, rinsed again in ethanol and left to air dry for 10 minutes. 
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IDH1 
GFAP ATRX 
Probes were applied following Abbott Vysis probes protocol (10μL in each slide). The 
incubation took place in a ThermoBrite Leica System Hybridizer, from Abbott 
Molecular, twenty minutes at 72ºC followed by overnight at 37ºC. 
The next day, slides were put in two post-hybridization solutions, first for about 10 
minutes, until the coverslips fell down, and second one, pre-heated at 75ºC, for 2 to 3 
seconds. 
Slides were rinsed in distilled water, stained with DAPI solution for one minute at RT, 
rinsed in tap water, dehydrated, cleared and mounted synthetic with mounting media, 
Entellan® (Appendix 2).  
 
4.4 Data Analysis 
4.4.1 ATRX, IDH1 and GFAP 
IHC slides were observed in bright-field microscope for staining quality control and 
photographed using Canon EOS 1200D camera, with a EF-S 18-55mm lens in auto 
mode. Images were saved in .tiff format and analysed in Image-J [59], using the colour 
deconvolution plugin.[60] Areas of interest – black – were measured and colours were 
assigned to black images, one for each antibody (Figures 5 and 6). Superimposition was 
made and those areas – primary colours – were measured. 
 
 
 
 
 
 
 
 
 
 
Primary colours areas represented subpopulations of tumor cells that expressed two 
proteins at the same time. Data was treated in pixels and final results were converted to 
percentages for easier understanding. 
 
Figure 5 - RGB and primary colour scheme used in Image-J analysis 
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Figure 6 - On top: Photographs from the IHC slides of one of the cases. Bellow: The isolation of the brown 
areas (expression of antibodies), converted in black. (From left to right: GFAP, IDH1 and ATRX) 
 
Original photographs were converted into black and white images, where the 
background was white and the brown marked areas were converted to black (Figure 6). 
Black and white images were then turned into RGB ones, were background colour was 
inverted to black and the marked areas were assigned with primary colours. Images 
were then overlapped and the colours added, resulting in a final image, where it was 
possible to visualize colocalization areas of both markers (Figure 7 and Table 1).  
 
 
Figure 7 - Overlap of two different antibodies (GFAP and ATRX) through the attribution of primary s to the 
stained areas. (GFAP - blue; ATRX - Green; Overlap - Cyan) 
 
 
Colour Deconvolution  
(Brown stain isolation is presented in black) 
28 
 
Table 1 - Image-J table of coloured Areas. 
  
 
The obtained table with the areas for each colour helped to identify the subpopulation 
we were looking for, namely: GFAP+ATRX+.  
4.4.2 Olig-2 and KI-67 
Afterwards, areas of the tumor slides imunnostained by Olig-2 and KI-67 were selected 
to be photographed. Three photographs per slide were obtained in bright-field 
microscope Leica DM 4000 B, using an amplification of 400x, and the ratio 
stained/non-stained cells was obtained in Image-J (Figure 8), with the plugin 
ImmunoRatio. [61] 
 
 
Figure 8 - Example of the application of the plugin ImmunoRatio in a sample slide stained for KI-67. Three 
distinct fields where photographed and the ratio between stained nuclei and non-stained nuclei were obtained. 
On top are the original photographs and at the bottom are the nuclei considered to the calculation. 
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4.4.3 FISH  
FISH slides were photographed in Fluorescence Microscope Leica DM 4000 B, using 
appropriate filters. Cells with amplification or deletion of the studied genes were 
counted (Table 2), using the plugin Cell Counter [62] on Image-J. 
 
Table 2 - Type of mutation by gene 
Gene Deletion Amplification Other Specifications 
1p    
19q    
CDKN2A    
PTEN    
P53    
EGFR   Simple Gene Amplification 
or Clusters 
 
 
4.4.4 Statistics 
Descriptive statistical analysis was performed. Numerical results from all cases were 
analysed using absolute values, and calculating mean and standard deviation for 
comparing purposes. Graphics were obtained using SigmaPlot 12.0, and tables were 
obtained using Excel and Image-J. 
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5. Results 
The study included 18 OLG, 3 OLGA, 10 AT and 1 Gliossarcoma (GS) (Table 3). 
Table 3- Proportion of samples in the study divided by histological classification 
 # Samples Percentage of total (%) 
Oligodendroglioma 18 56,250 
Oligoastrocytoma 3 9,375 
Astrocytoma 10 31,250 
Gliossarcoma 1 3,125 
Total 32 100,000 
 
Five antibodies were studied in each sample, resulting in a total of 160 IHC slides. 
 From primary to relapse tumors, the expression of KI-67 is generally higher in 
relapses (Figure 9). The maximum percentage of expression for KI-67 was 
17,1%, in a relapse sample (Figure 10). The opposite is observed in Olig-2, 
where primary samples presented higher values compared to relapses (Figure 11 
and 12).  
 
Figure 9 - Example of the evolution of KI-67 from primary tumor sample (top images) to relapse 
tumor sample (bottom images). Three fields of each slide were photographed and the DAB/Nuclear 
area average ratios found were: Primary tumor sample – 3,4% and Relapse tumor sample – 8,6%. 
31 
 
 
 
 
 
Figure 10 - Evolution of the expression of individual markers from primary tumors to their relapses. 
 
 
Figure 11 - Example of the evolution of Olig-2 from primary tumor sample (top images) to relapse 
tumor sample (bottom images). Three fields of each slide were photographed and the DAB/Nuclear 
area average ratios found were: Primary tumor sample – 84,3% and Relapse tumor sample – 50,7%. 
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Figure 12 - Evolution of the expression of individual markers from primary tumors to their relapses. 
 
 IDH1 areas showed a reduction or no changes in most cases and ATRX areas 
were reduced and increased in the same proportion (Figure 13). Percentage of 
IDH1mut areas found was generally low, varying between 0 and 3,38%.  
 
 
Figure 13 - Evolution of the expression of individual markers from primary tumors to their relapses. 
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Figure 13 (cont.) - Evolution of the expression of individual markers, from primary tumors to their 
relapses. 
 
 It was possible to identify tumor cells subpopulations with different protein 
expression combinations. As mentioned above, this analysis was based on the 
study of different layers of the same tumor samples and the following 
comparison between the subpopulations found in primary and relapse tumors 
(Figure 14). 
 
Figure 14- Illustration of the layered analysis performed in the samples showing the colocalization spots of two 
antibodies, which represent subpopulations of cells with different protein expressions. 
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 When searching for subpopulations of tumor cells, the following ones were 
studied, initially: 
 
 
Figure 15- Tumor Subpopulations of cells studied. 
 
The above subpopulations (Figure 15) were obtained using the following formulas: 
Table 4 – Formulas used for the calculation of areas 
Subpopulation Used formula  Explanation 
IDH1+ATRX- A = R Area obtained equals area of red.  
IDH1+1p19qco-del A = (R + Y) ∩ co-del Area obtained is the result of red plus 
yellow areas and the intersection of 
that value with 1p19q co-deleted areas. 
IDH1- A = ?̅?  B - R Area obtained equals area of non-red, 
which means is the subtraction of red 
from blue (total).  
Note:   
 IDH1+ = mutation (detected by IHC) 
 IDH1- = WT protein (undetected by IHC) 
 ATRX+ = presence of protein (detected by IHC) 
 ATRX- = loss of protein (undetected by IHC) 
 
 
Histomorphological classification of glioma 
IDH1+  mut 
ATRX-  loss (mut) 
IDH1+  mut 
1p19q  co-del 
IDH1-  wild-type 
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 As showed in Figure 16, IDH1mut/ATRXloss area presents very close values in 
both groups – primaries and relapses, being mean and standard deviation 
5053±10116 from primaries and from relapses. Linearized ratio between these 
two groups obtained by Pearson’s correlation coefficient is p=0,852 with 
relapses tumor samples presenting a bigger area expressing IDH1mut/ATRXloss 
cells. 
 
 
 
 
 
Figure 16 – Comparison of mean values of subpopulations of tumor cells from primary tumors to their 
relapses. 
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 Regarding IDH1wt cells, values are inverted with a p-value of -0,432, where 
primary tumors group mean and standard deviation is 671939±180448 and the 
relapses group is 609653±284091 (Figure 17). 
 
 
 
 
 
 
Figure 17 - Comparison of mean values of subpopulations of tumor cells from primary tumors to their 
relapses. 
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Table 5 shows the relation between IDH1mut/ATRX subpopulations and 1p19q co-
deletion. 
Table 5 - IDH1mut/ATRX/1p19q co-deleted subpopulations 
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0,00 34,31 22,40 
 
0,86 45,45 20,29 
2 
 
0,00 36,07 28,97 
 
0,00 14,42 17,79 
3 
 
0,07 13,75 2,26 
 
0,04 9,56 3,76 
4 
 
0,00 6,03 6,90 
 
0,11 17,09 9,09 
5 
 
1,96 8,59 12,16 
 
0,89 6,56 7,94 
6 
 
0,03 8,77 8,19 
 
0,00 9,33 5,07 
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Table 5 (cont.) - IDH1mut/ATRX/1p19q co-deleted subpopulations 
C
a
s
e
 
 Primary Tumor  Relapse Tumor 
Image  %
 
ID
H
1
+
/A
T
R
X
+
 
%
 1
p
 
d
el
et
ed
 
%
 1
9
q
 
d
el
et
ed
 
Image  %
 
ID
H
1
+
/A
T
R
X
+
 
%
 1
p
 
d
el
et
ed
 
%
 1
9
q
 
d
el
et
ed
 
7 
 
0,44 33,90 4,85 
 
0,00 7,80 1,24 
8 
 
0,00 10,37 24,53 
 
0,11 11,36 26,04 
9 
 
0,00 9,35 16,24 
 
0,00 18,67 30,33 
10 
 
0,87 9,57 62,96 
 
0,00 3,54 28,48 
13 
 
0,00 0,00 11,43 
 
9,44 18,64 7,14 
14 
 
0,14 1,89 10,00 
 
0,00 3,82 11,36 
 
 Of all IDH1mut/ATRX primary tumors, only about 33% maintained this 
expression in relapses. Regarding primary tumors without IDH1mut/ATRX 
expression, 40% started to express both these markers in relapses. 
IDH1mut/ATRX/1p/19q co-deleted cells were found in only 1 out of 16 cases. 
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 1p gene was found deleted in only 4 samples, being 3 OLG (two low-grade) and 
1 AT (low-grade).  
19q gene was found deleted in 5 samples, being 3 OLG (one low-grade) and 2 
AT (1 low-grade and 1 higher-grade). 
Co-deletion of 1p/19q was only found in 1 case of low-grade OLG which 
relapsed in a higher-grade OLG with no deletions of these genes. 
 
Although it was not the focus of the study, comparison between diagnostic groups was 
performed, for subpopulations. Histological classifications were assigned according to 
WHO parameters approved prior to the 2016 review.  
 
 
 
 
Figure 18- Comparison of mean values of subpopulations of tumor cells among different groups based in 
histomorphological diagnosis. 
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Figure 18 (cont.) - Comparison of mean values of subpopulations of tumor cells among different groups based 
in histomorphological diagnosis. 
 
 Figure 18 shows IDH1mut/ATRXloss area means values and respective standard 
deviations decreases in the following order OLG (10562,72±23719,45), OLGA  
(6708,33±11619,17), AT (2738,40±6199,81), and GS (0). 
 Regarding IDH1wt cells, values vary in almost the same order of categories, 
decreasing from GS (1318048) to OLGA (640779,7±156722,6), to AT 
(640361,2±216242,5), to OLG (603415,7±213690,4).  
 
 We found 57% of primary tumors with IDH1 mutation kept it in their 
correspondent relapses. (Figure 19). From primary tumors without this mutation, 
about 56% developed it in relapses (Figure 19). 
 
 
 
 
 
 
41 
 
Primary Tumor Sample: % IDH1 mutations 
 
Relapse Tumor Sample: % IDH1 mutations  
and WT IDH1 
 
 
Primary Tumor Sample: % WT IDH1 
 
 
 
 
 
 
 
Relapse Tumor Sample: % IDH1 mutations  
and WT IDH1 
 
Figure 19 - IDH1 mutation profiles in primary and relapse tumors. 
 
 FISH analysis of the other probes, showed the percentage of nuclei with deletion 
of tumor suppressor gene PTEN was low in all samples, ranging from 1,78% to 
14,29%. [63] 
 
 EGFR study showed amplification in 6 of 32, of which four correspond to AT (1 
primary and 3 relapses, most of them with multiple copies of the gene and only 
1 with clusters), and 2 correspond to OLG, both in relapses with more than 4 
copies (Table 6). 
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Table 6 - EGFR FISH positive results. 
Sample 
Tumor Diagnosis 
EGFR 
% clusters % 4 copies % > 4 copies 
12 Relapse Oligodendroglioma 4,65 9,30 13,95 
13 Primary Astrocytoma 6,06 9,09 15,15 
14 Relapse Astrocytoma 4,00 9,71 13,71 
16 Relapse Oligodendroglioma 5,43 5,43 10,85 
20 Relapse Astrocytoma 13,04 0,00 13,04 
28 Relapse Astrocytoma 7,30 13,87 21,17 
 
Comparing the differences from primary tumors to their relapses (Figure 20), in 4 cases 
EGFR was not amplified in the primary and became amplified in some form in the 
relapse, namely 1 astrocytoma which relapsed as an OLG (EGFR variation from 0 
clusters + 5,71% 4 copies + 5,71% > 4 copies to 4,65% clusters + 9,30% 4 copies + 
13,95% > 4 copies); 1 primary OLG (6,52% 4 copies + 6,52% > 4 copies) which 
relapsed as a higher-grade OLG (5,43% clusters + 5,43% 4 copies + 10,85% > 4 
copies); 1 low-grade AT (4,76% clusters + 4,76% 4 copies + 9,52% > 4 copies) which 
relapsed as a higher-grade AT (13,04% clusters + 13,04% > 4 copies) and 1 AT with 
no amplification of any kind in the primary which relapsed as a higher-grade AT with 
7,30% clusters + 13,87% 4 copies + 21,17% > 4 copies.  
 
 
 
 
 
Figure 19- Variations found in EGFR, increase in amplification from primary tumor samples to relapses. 
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Figure 20 (cont.) - Variations found in EGFR, increase in amplification from primary tumor samples to 
relapses. 
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One case presented with reduced amplification from primary tumor to relapse (Figure 
21 and Appendix 3), namely an AT with 6,06% clusters + 9,09% 4 copies + 15,15% > 
4 copies which relapsed a similar higher-grade with 4,00% clusters + 9,71% 4 copies + 
13,71% > 4 copies. These values seam almost virtually equal and this difference is 
probably related to the sampling location. 
 
  
Figure 20 - Variations found in EGFR, decrease in amplification from primary tumor samples to relapses. 
 
 P53 was mutated in 6 samples, being 2 OLG, 2 OLGA and 2 AT. 4 of all 6 
mutations occurred in relapses (Table 7). Analysing the changes from primary 
tumor samples to relapse samples, we found 4 cases with WT p53 in the primary 
tumors and mutation in relapses and 1 case that kept the mutation in both 
surgeries. 
Table 7 - p53 mutations. 
 
Sample Tumor Diagnosis % p53 mutation  
8 Relapse Oligodendroglioma 34,21 
17 Primary Oligoastrocytoma 43,88 
24 Relapse Oligoastrocytoma 37,29 
26 Relapse Oligodendroglioma 26,39 
31 Primary Astrocytoma 26,25 
32 Relapse Astrocytoma 32,63 
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Analysing variations from primary tumors to correspondent relapses (Appendix 4), we 
found 3 cases (OLG) that had wild-type p53 gene in primary tumors and mutated form 
in relapses (Figure 22); 1 OLGA with mutation in the primary tumor which relapsed as 
OLG without mutation. We also found 1 low-grade AT that kept p53 mutation in its 
higher-grade relapse (samples 31 and 32). As shown in the table above, the variation 
went from 26,25% to 32,63%, raising about 6,38% from primary to relapse.   
 
 
Figure 21 - p53 mutations found in primary tumor samples and relapses. 
 
 Concerning CDKN2A deletions (Figures 23 and 24), we found only 1 case with 
deletion in both primary tumor and relapse. Results showed 6 cases with 
deletion in primary tumor and only 3 in the higher-grade relapses. 
Observing histology-based diagnosis, it is found that CDKN2A is deleted in a 
proportion of ½ of AT to OLG (3 AT and 6 OLG, low-grade or higher-grade). 
We found the percentages of nuclei with CDKN2A deletion ranged from 2,92% 
to 39,60%, with 9 samples with values over 25%, which can be considered high 
values (Figure 24). 
 
 
 
46 
 
 
 
Figure 22 - Percentage of CDKN2A deletions in primary tumor samples vs. relapses. 
 
 
Figure 23 - FISH results for CDKN2A deletion. 
 
 
The following table (Table 8) summarizes the differences found between both groups 
for each marker: 
 
 
Primary Diagnosis % CDKN2A nucleus with deletion Relapse Diagnosis % CDKN2A nucleus with deletion 
1 Oligodendrogliomas 13,68 2 Oligodendrogliomas 10,00
3 Oligodendrogliomas 6,56 4 Oligodendrogliomas 7,76
5 Oligodendrogliomas 39,22 6 Oligodendrogliomas 20,71
7 Oligodendrogliomas 20,68 8 Oligodendrogliomas 2,92
9 Oligoastrocytomas 23,38 10 Oligodendrogliomas 17,89
11 Astrocytomas 12,00 12 Oligodendrogliomas 14,29
13 Astrocytomas 6,74 14 Astrocytomas 7,43
15 Oligodendrogliomas 15,79 16 Oligodendrogliomas 20,59
17 Oligoastrocytomas 39,60 18 Oligodendrogliomas 11,11
19 Astrocytomas 12,50 20 Astrocytomas 31,34
21 Oligodendrogliomas 23,58 22 Oligodendrogliomas 34,83
23 Oligodendrogliomas 26,92 24 Oligoastrocytomas 14,12
25 Oligodendrogliomas 31,29 26 Oligodendrogliomas 36,36
27 Astrocytomas 9,09 28 Astrocytomas 21,01
29 Astrocytomas 35,71 30 Gliossarcoma 18,75
31 Astrocytomas 31,25 32 Astrocytomas 16,13
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Table 8 - Summary of differences found in markers studied between primary tumors and relapse tumors. 
Markers 
Primary Tumor (P) Relapse Tumor (R) Variance  
(R –P) 
 
Mean 
Standard 
Deviation 
Mean 
Standard 
Deviation 
KI-67 expression (%) 4,99 3,64 7,05 4,34 2,06 
Olig-2 expression (%) 48,52 23,57 40,50 25,58 -8,02 
IDH1 mut (Pixels) 5052,63 10116,73 9799,00 24383,90 4746,38 
WT IDH1 (Pixels) 671939,00 180448,00 609653,00 284091,00 -62286,00 
ATRX loss (Pixels) 398233,75 209797,66 354239,81 258052,35 -43993,90 
EGFR 
(%) 
4 copies 2,63 2,88 2,96 4,32 0,32 
>4 copies 4,86 4,31 6,26 6,31 1,40 
clusters 2,23 2,71 3,31 3,41 1,08 
CDKN2A deletion (%) 21,75 11,35 17,83 9,69 -3,92 
p53 mutation (%) 17,90 8,29 17,68 10,17 -0,22 
PTEN loss (%) 7,72 3,07 7,07 3,15 -0,64 
1p (%) 12,65 11,44 12,27 10,40 -0,38 
19q (%) 15,88 15,21 14,19 9,27 -1,69 
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6. Discussion and conclusions 
Diffuse gliomas are generally characterized by infiltration of the surrounding brain 
tissue, fact that originates fast progression and relapses.[64] 
The role of individual oncogenes and tumor suppressors in the initiation of low-grade 
gliomas remains poorly understood.  
Several lines of evidence support the notion that the IDH1 mutation is the inciting 
oncogenic hit in LGG.[65]  
Johnson et al., through exome sequencing of IDH-mutated AT at initial diagnosis and 
recurrence showed that, while the IDH1 is preserved, distinct clonal mutations in P53 
and ATRX emerge at recurrence.[66]  
Similarly, our general analysis detected 4 cases in which p53 mutations appeared in 
relapses and 8 cases which lost ATRX gene, as stressed by that author, “…the recurrent 
tumor contained driver mutations in TP53 and ATRX distinct from those observed in the 
initial tumor”.[66] 
It is thought that expression of mutant IDH1 alone in progenitor cells leads to pre-
tumorigenic changes.[65] 
Also, loss of ATRX by itself in a wild-type p53 background does not lead to brain tumor 
formation. Likewise, p53 loss in brain cells does not result in tumor formation by itself, 
unless other oncogenes are introduced.[65] Modrek et al. 
propose that the most likely order of the 3 oncogenic hits is 
IDH mutation, followed by loss of p53 and finally loss of 
ATRX. 
In literature, 3 distinct lines of mutation-based tumors (Figure 
25) have been distinguished.[67] Our analysis of these 3 
groups suggests that timeline of mutations may be variable – 
 Indeed we show tumors with p53 mutations and 1p19q co-
deletions that keep WT IDH1, while IDH1 mutation has been 
described to be the putative first event in gliomas’ 
oncogenesis. 
In one study, nearly all lower-grade gliomas with IDH 
mutations and no 1p/19q co-deletion had mutations in p53 (94%) and ATRX inactivation 
(86%). [31] 
Figure 24 - Three lines of 
mutations-based tumors 
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According to our analysis, all lower-grade gliomas with IDH mutations and no 1p/19q 
co-deletion had a relatively high percentage of ATRX loss, but p53 values for mutation 
were low. 
As expected, in our series, relapse tumors showed higher values of KI-67, meaning a 
higher cellular proliferation, while primary tumors displayed lower values. 
Olig-2, which marks oligodendrocyte lineage genes expressed in glial cells, showed 
practically inverted results, with the higher values in primary tumors. This fact was also 
expected since tumors tend to loose differentiation with malignance progression. 
Areas of IDH1+ATRX- found in both groups – primaries (low-grade) and relapses 
(higher grade) – are very similar, however the second group presents higher area values, 
meaning more tumoral cells with IDH1 mutation and ATRX loss. As presented above, 
56% of primary tumors without IDH1 mutation developed this expression in their 
correspondent relapses, which raises the question if first tumour mutation went 
undetected, either by limitations of neuropathological examination or incomplete 
resection at surgery. 
The results may show that oncogenic progression is based on such mutated cells. The 
identification of such a cell type may be important to establish aggressiveness of 
primary tumours in a diagnostic context. 
As said, mutations of IDH and ATRX occur in early stage of gliomagenesis and 
characterize specific subtypes of gliomas in adults.[67] 
IDH1 mutation has been shown to play an important role in the process of angiogenesis, 
cell survival and proliferation. Although this mutation would promote tumor growth, it 
commonly indicates a favourable prognosis independent of WHO grades.[67]  
ATRX loss was recently identified as a potent biomarker in grade II-III gliomas and was 
associated with recurrency.[67] 
Regarding IDH1+ATRX expression in primary tumors and relapses, sampling could 
play a factor in the observed results. Tumours were included in the study only if 
recurrence existed. Boots-Sprenger et al. and Xin, H. et al. demonstrate the favourable 
outcome of 1p19q deletion, meaning the inclusion criteria could easily bias the 
identification of such co-deletion.[38, 68] 
Bortolotto et al. studied CDKN2A homozygous deletion in 25 cases of OLG and found 8 
positive cases. It was showed that CDKN2A did not correlate with histological grading; 
however, it showed a significant correlation with survival, supporting the hypothesis of 
an important role of this gene in prognosis of OLG. 
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Our results corroborate these findings. We identified 6 cases with deletions in low-grade 
gliomas and only 3 in higher-grade gliomas, supporting that there is no correlation with 
histological grading. CDKN2A was deleted in both groups in only 1 sample. 
CDKN2A deletion is strongly associated with poorer overall survival in AT but not in 
OLG or OLGA. We found deletion of CDKN2A in both AT and OLG/OLGA. 
Molecular classification of AT by IDH mutation, p53 mutation, and/or ATRX loss of 
expression revealed that CDKN2A loss in IDH/p53 mutated tumours was strongly 
associated with worse overall survival. CDKN2A loss in IDH mutated tumors with 
ATRX loss was only weakly associated with worse overall survival.[58] 
Sibin et al refers many studies including previous studies from his lab indicated that 
alterations in p16 gene and its expression are common in glioma and the CDKN2A/B 
rs4977756 polymorphism shows obvious increase in the risk of glioma in 
Caucasians.[69] Our results are based on deletions of the CDKN2A gene. Gene analysis 
may identify not only deletions but structural changes that determine CDKN2A 
influence in tumour progression. Therefore, CDKN2A is associated with bad prognosis 
and usually presents low values. P16 analysis would be important to identify gene 
alterations other than deletions, in which FISH technique is based. The use of p16 
immunohistochemistry could have valuable prognostic factor. 
Percentage of CDKN2A deletion decreased in relapses: 8 of the 16 samples presented a 
deletion above 25% and 6 of which were primary tumors. 
These results may suggest this gene could be related with gliomas’ aggressiveness and 
this may be a key-marker in determining the prognosis of LGG. 
The alteration of certain other well-known pro-oncogenes and tumor-suppressor genes 
in patients with AOLG was identified, such as mutations in phosphatidylinositiol 3-
kinase (1PI3K), amplification of  EGFR or loss of PTEN tumor suppressor.[70] EGFR 
gene amplification and overexpression are rare in low-grade gliomas but are very 
typical in GB.[43-44]  
Our data showed EGFR amplification in about one fifth of the samples. These results 
are supporting the findings described. There was 1 case with amplification exclusively 
in the primary tumor. Those values seam almost virtually equal and this difference is 
probably related to the sampling location. 
Nevertheless, lower percentages of PTEN deletions were found in our samples, 
suggesting this marker is probably not one of the key-markers in gliomas’ 
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aggressiveness. Similar results were found for p53, interestingly both being the main 
tumor suppressors mutated in most solid cancers.  
 
In conclusion, the differences in the populations (IDH1mut/ATRXloss, 
IDH1mut/ATRX/1p/19q co-del and IDH1wt) between primary tumor samples and their 
relapses studied by us, are subtle and perhaps biological drive towards malignancy 
cannot be distinguished using these markers alone. 
We did find differences in genetic and immunohistochemical markers, mainly: Ki-67, 
Olig-2, EGFR and CDKN2A. [67, 69] Our samples showed multiple genetic events and 
led us to think tumour relapses need to be studied with clinical data, especially survival 
that might allow a clearer view of distinguishable paths towards oncogenicity. We 
found differences in some putative oncogenic pathways. Relapses seem, when 
considered as whole entity, to have proliferation and oncogenic pathways, like EGFR, 
different from the original tumour, howbeit small in number.  
The reduced number of cases is a limitation to this study. Also, FISH analysis in TMA 
samples instead of the whole extension of the tumors was a limitation as well, and this 
decision was linked to the lack of time necessary to perform such time consuming 
technique. Our choices tried to overcome such limitations, since the sample size is 
considerable, based in our bibliographic search. FISH was performed at tumour site, 
choosing tumour cells that were representative of the whole tumour. Extensive genetic 
analysis, ideally next generation sequencing, could not be performed but would 
complement our findings with a clearer genetic profile of low grade gliomas in our 
population. 
It should be interesting to continue this line of research, comparing primary tumors with 
their own relapses, since there are very few papers published with similar cases; perhaps 
using DNA sequencing instead of FISH techniques, and comparing the results with real 
survival rates and patient outcomes.  
The objective is not just to characterise histological subgroups of gliomas, but also to 
try to understand what protein or genetic component in the tumor is responsible for the 
relapse in a much more aggressive form. Predicting such behaviour could mean better 
chances of controlling the progression of the disease right in the moment of the first 
diagnosis. 
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8. Appendixes 
 
8.1 Appendix 1: IHC technique protocol 
1. Dewax and hydration  
2. Endogenous peroxidase inhibition – 3% - 10m 
3. Antigen retrieval – H3300 vector citrate buffer (9,375mL to 1L H2Od), Microwave: 
600W/10m + 850W/20m 
4. Cooling and assembling on Sequenza with PBS buffer 
5. Rinse with PBS 
6. Incubation of primary antibody – ON at 4ºC 
7. Rinse twice with PBS 
8. Incubation of secondary antibody – 1hour at RT 
9. Rinse twice with PBS 
10. Disassemble and revelation with DAB – 5m 
11. Rinse in tap water 
12. Counterstain in Harris Hematoxylin – 4m 
13. Rinse in tap water 
14. Differentiate in 1% hydrochloric alcohol 
15. Rinse in tap water 
16. Blue with 1% ammoniacal water  
17. Rinse in tap water 
18. Dehydrate, clear and mount with mounting media 
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8.2 Appendix 2: FISH technique protocol 
1. Dewax and hydration  
2. Antigen retrieval – H3300 vector citrate buffer (9,375mL to 1L H2Od), Microwave: 
600W/10m + 850W/20m 
3. Pre-hybridization solution – sodium thiocyanate – 82ºC/10m 
4. Ethanol  
5. Digestion solution – pepsin – 37ºC/10m 
6. Ethanol 
7. Air Dry 
8. Incubate the probes in the slides and cover with the coverslips 
9. Place slides on the hybridizer and define programme (60min between 55º - 62ºC; 2min 
at 95ºC; ON at 37ºC) 
10. Post-hybridization solution I – 10m (or until the coverslips fall out) 
11. Post-hybridization solution II – 75ºC/3 seconds with agitation  
12. Rinse in distilled water 
13. Counterstain with DAPI – 2m 
14. Dehydrate, clear and mount with mounting media 
 
 
8.3 Appendix 3: EGFR FISH results 
 
 
 
 
 
 
Primary Diagnosis % EGFR CLUSTERS % EGFR  4 COPIES %EGFR > 4 COPIES Relapse Diagnosis % EGFR CLUSTERS % EGFR  4 COPIES %EGFR > 4 COPIES
1 Oligodendrogliomas 0,00 2,86 2,86 2 Oligodendrogliomas 0,85 0,00 0,85
3 Oligodendrogliomas 4,55 0,00 4,55 4 Oligodendrogliomas 0,90 2,70 3,60
5 Oligodendrogliomas 2,50 0,00 2,50 6 Oligodendrogliomas 1,67 0,00 1,67
7 Oligodendrogliomas 0,91 1,82 2,73 8 Oligodendrogliomas 2,19 2,19 4,38
9 Oligoastrocytomas 0,00 0,00 0,00 10 Oligodendrogliomas 3,97 0,79 4,76
11 Astrocytomas 0,00 5,71 5,71 12 Oligodendrogliomas 4,65 9,30 13,95
13 Astrocytomas 6,06 9,09 15,15 14 Astrocytomas 4,00 9,71 13,71
15 Oligodendrogliomas 0,00 6,52 6,52 16 Oligodendrogliomas 5,43 5,43 10,85
17 Oligoastrocytomas 0,00 0,00 0,00 18 Oligodendrogliomas 0,00 0,00 0,00
19 Astrocytomas 4,76 4,76 9,52 20 Astrocytomas 13,04 0,00 13,04
21 Oligodendrogliomas 7,41 2,22 9,63 22 Oligodendrogliomas 1,79 1,79 3,57
23 Oligodendrogliomas 3,45 5,75 9,20 24 Oligoastrocytomas 0,00 0,56 0,56
25 Oligodendrogliomas 0,00 1,67 1,67 26 Oligodendrogliomas 0,00 0,00 0,00
27 Astrocytomas 0,00 0,00 0,00 28 Astrocytomas 7,30 13,87 21,17
29 Astrocytomas 6,00 0,00 6,00 30 gliossarcoma 5,17 0,00 5,17
31 Astrocytomas 0,00 1,74 1,74 32 Astrocytomas 1,92 0,96 2,88
62 
 
8.4 Appendix 4: p53 FISH results 
 
Primary Diagnosis p53 mutation Relapse Diagnosis p53 mutation
1 Oligodendrogliomas 17,33 2 Oligodendrogliomas 10,34
3 Oligodendrogliomas 15,38 4 Oligodendrogliomas 10,64
5 Oligodendrogliomas 12,00 6 Oligodendrogliomas 8,39
7 Oligodendrogliomas 10,74 8 Oligodendrogliomas 34,21
9 Oligoastrocytomas 20,74 10 Oligodendrogliomas 6,80
11 Astrocytomas 23,26 12 Oligodendrogliomas 16,98
13 Astrocytomas 16,09 14 Astrocytomas 13,20
15 Oligodendrogliomas 12,50 16 Oligodendrogliomas 20,96
17 Oligoastrocytomas 43,88 18 Oligodendrogliomas 22,95
19 Astrocytomas 20,00 20 Astrocytomas 11,76
21 Oligodendrogliomas 14,40 22 Oligodendrogliomas 10,68
23 Oligodendrogliomas 9,90 24 Oligoastrocytomas 37,29
25 Oligodendrogliomas 14,20 26 Oligodendrogliomas 26,39
27 Astrocytomas 12,34 28 Astrocytomas 12,95
29 Astrocytomas 17,39 30 gliossarcoma 6,67
31 Astrocytomas 26,25 32 Astrocytomas 32,63
